Hashim, Dana
Engesæter, Birgit
Baadstrand Skare, Gry
Castle, Philip E.
Bjørge, Tone http://orcid.org/0000-0002-9096-5257
Tropé, Ameli
Nygård, Mari http://orcid.org/0000-0002-4100-4855
Funding for this research was provided by:
Kreftforeningen (564906, 564906, 564906, 564906, 564906, 564906)
Article History
Received: 30 August 2019
Revised: 3 February 2020
Accepted: 12 February 2020
First Online: 3 April 2020
Ethics approval and consent to participate
: This study was approved by the Regional Committee for Medical and Health Research Ethics (REK) in South East Norway (REK reference number 2017/1910). REK has given exemption from the consent requirement pursuant to the Norwegian Health Research Act § 35. This exemption is provided that the research in question is of significant interest to society, and the welfare and integrity of the participants is ensured. The specific purpose of this project is to improve cervical cancer prevention and diagnose the disease earlier. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: All data not included in this published article are available upon reasonable request from the Cancer Registry of Norway.
: P.E.C. has received cervical screening tests and diagnostics from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation at a reduced or no cost for research. All other authors report no competing interests.
: This work is supported by a grant from the Norwegian Cancer Society, project ID: #564905. Sponsors had no role in study design, data collection, analysis, and interpretation of data; in the writing of the report or the decision to submit the article for publication.